A new online toolkit by the National Organization for Rare Disorders aims to tackle the issue of diversity, equity and inclusion (DEI) in rare diseases by providing a list of best practices as well as a glossary aimed at non-profits. But the group said small biotech companies could also benefit, particularly by finding ways to work with non-profits, at a time when many large drug makers have been touting their own DEI efforts, especially clinical research in more common diseases like breast cancer and COVID-19 as well as in improving diversity within their organizations.
NORD launched the first of a series of online toolkits on 3 March focused on DEI and how the lack...